Novo Nordisk A/S (NYSE:NVO)

111.59
Delayed Data
As of Jul 01
 +0.16 / +0.14%
Today’s Change
83.86
Today|||52-Week Range
122.16
-0.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$195.0B

Company Description

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Contact Information

Novo Nordisk A/S
Novo Allé 1
Bagsværd Capital Region 2880
P:(454) 444-8888
Investor Relations:
(453) 075-2175

Employees

Shareholders

Other institutional7.21%
Mutual fund holders0.91%
Individual stakeholders--

Top Executives

Lars Fruergaard JørgensenPresident & Chief Executive Officer
Maziar Mike DoustdarExecutive Vice President-International Operations
Karsten Munk KnudsenChief Financial Officer & Executive Vice President
Henrik Ehlers WulffExecutive VP & Head-Information Technology
Stephen GoughGlobal Chief Medical Officer